Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-07-22
Item 5.07
This is a clear disclosure of shareholder vote results from Capital Southwest Corporation's 2026 Annual Meeting held on July 22, 2026. The filing reports voting outcomes for six proposals: election of six directors, advisory approval of named executive officer compensation, frequency of advisory compensation votes, ratification of RSM US LLP as independent auditor, and approval to adjourn for a Charter Amendment vote. The detailed vote tallies (votes for, against, abstentions, and broker non-votes) for each proposal are the core content of Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
Hudson Acquisition I Corp. held a Special Meeting of stockholders on July 17, 2026, where shareholders voted to approve an Extension Amendment extending the deadline for completing a Business Combination from July 18, 2026 to April 18, 2027 (with up to nine one-month extensions), and approved an adjournment proposal. Both proposals passed overwhelmingly with 2,070,575 votes in favor, 2 against, and 0 abstentions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-22
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of an annual shareholder meeting held on July 16, 2026. The filing presents voting outcomes on three proposals: election of Class I directors (Richard Booth and Christine Detrick), advisory approval of named executive officer compensation, and ratification of Grant Thornton LLP as independent auditors. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core content of the disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This disclosure reports the results of a special shareholder meeting held on July 16, 2026, where security holders voted on two proposals: approval of a plan of liquidation and dissolution of the Fund, and termination of its BDC status under the Investment Company Act of 1940. Both proposals passed with 70.45% approval from LLC Members (the beneficial owners). This is a classic shareholder vote result disclosure under Item 5.07, and the liquidation and BDC termination constitute material events affecting the registrant's continued existence and status.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-22
EX-99.1
This press release discloses the results of a Special Meeting of Shareholders held on July 22, 2026, where Equinox Gold shareholders voted to approve the share issuance resolution in connection with the proposed business combination with Orla Mining Ltd. The voting results show 507,548,903 votes in favor (99.83%) and 866,815 against (0.17%), representing 64.43% of outstanding shares. This is a material shareholder vote result directly tied to a significant M&A transaction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of ZW Data Action Technologies' Annual Meeting of stockholders held on July 22, 2026, including voting outcomes on four matters: election of seven directors, ratification of independent accountants (ARK Pro CPA & Co.), ratification of the 2026 Omnibus Equity Incentive Plan, and approval of an increase in authorized shares. The detailed voting tallies (For/Against/Abstain/Broker Non-Votes) for each proposal are the core content of this filing, which is the standard form and substance of a shareholder vote results disclosure under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the final voting results from Genesco Inc.'s Annual Meeting of Shareholders held on July 21, 2026, including election of nine directors, advisory approval of named executive officer compensation, approval of the Fourth Amended and Restated 2020 Equity Incentive Plan, and ratification of Deloitte & Touche LLP as independent auditor. The filing presents tabulated vote counts for each matter, which is the core purpose of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-22
Item 5.07
This Item 5.07 discloses the results of a special stockholder meeting held on July 22, 2026, where TMHC shareholders voted on three proposals: (1) adoption of a Merger Agreement with Berkshire Hathaway Inc. (75,830,360 votes for, 2,333,091 against), (2) advisory approval of executive compensation in connection with the merger (70,009,828 for, 8,095,053 against), and (3) an adjournment proposal (not submitted). The merger proposal received overwhelming shareholder approval, making this a material shareholder vote result that directly enables the M&A transaction to proceed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of Spok Holdings' 2026 Annual Meeting of Stockholders held on July 21, 2026, including voting outcomes for director elections (six directors elected), ratification of Grant Thornton LLP as independent auditor, advisory approval of NEO compensation, and approval of the amended 2020 Equity Incentive Award Plan. The detailed vote tallies (For, Withheld, Abstentions, Broker Non-Votes) for each matter are presented in tabular form, which is the standard format for shareholder vote result disclosures under Item 5.07.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-22
The 6-K discloses the Final Synthetic Voting Map for an Extraordinary General Meeting held on April 30, 2026, presenting voting results for the election of Board of Directors members (items 1.1 and 1.2) and the election of the Chairman of the Board (items 2.1 and 2.2), with vote tallies representing 82.4% of voting capital. This is a direct disclosure of shareholder vote results as required by CVM Resolution No. 81/2021.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-22
This exhibit is the official minutes of Vale's Extraordinary General Meeting held on July 22, 2026, disclosing shareholder voting results on three agenda items: removal of Daniel André Stieler (rendered moot by his prior resignation), election of Ieda Gomes Yell as an independent Board member (2,400,170,665 votes in favor), and election of Manuelino Silva de Sousa Oliveira as Chairman (1,977,262,848 votes in favor). The document explicitly records voting tallies, candidate information, and shareholder participation at 82.4% of share capital, making this a material governance event affecting board composition.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 85%
filed 2026-07-22
EX-99.1
Intercure Ltd. is soliciting shareholder approval for a reverse 5-to-1 share split and amendment to the Articles of Association at an Extraordinary General Meeting scheduled for August 12, 2026. The reverse split is driven by a Nasdaq non-compliance notice received on February 25, 2026 for failing to maintain a minimum $1.00 bid price, with delisting risk if the reverse split is not approved by the August 24, 2026 deadline.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of the Company's 2026 Annual Meeting of Members held on July 17, 2026, including voting outcomes on two matters: (1) re-election of three Class I directors (David R. Adler, Sheila A. Finnerty, and Andrew W. Tarica) with unanimous approval (3,753,190 votes for, 0 withheld), and (2) ratification of Deloitte & Touche LLP as independent auditor with unanimous approval (3,753,190 votes for, 0 against). The disclosure directly matches the shareholder_vote_results category as it presents formal voting results from an annual meeting of security holders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of the Company's 2026 Annual Meeting of Members held on July 17, 2026, including voting outcomes on two matters: (1) re-election of three Class I directors (David R. Adler, Sheila A. Finnerty, and Andrew W. Tarica) with unanimous approval (3,224,700 votes for, 0 withheld), and (2) ratification of Deloitte & Touche LLP as independent auditor with overwhelming approval (3,217,200 for, 7,500 against). This is a classic shareholder vote results disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of TCW Direct Lending VII LLC's 2026 Annual Meeting of Members held on July 17, 2026. The filing presents voting outcomes for two matters: (1) re-election of three Class II directors (David R. Adler, Sheila A. Finnerty, and R. David Kelly) with unanimous approval (9,099,650 votes for, 0 withheld), and (2) ratification of Deloitte & Touche LLP as independent auditor with overwhelming approval (9,097,650 for, 2,000 against). This is a straightforward shareholder vote results disclosure, material to investors as it confirms board composition and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This Item 5.07 disclosure reports the results of TCW Direct Lending LLC's 2026 Annual Meeting of Members held on July 17, 2026, including voting outcomes on three matters: re-election of a Class III director (David R. Adler), ratification of Deloitte & Touche LLP as independent auditor, and approval of a one-year extension of the Company's term. The filing presents vote tallies (For, Against, Withheld, Abstained, Broker Non-Votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-07-22
Item 5.07
Avanos Medical stockholders voted on July 22, 2026 to approve a merger agreement with American Industrial Partners affiliates at $25.00 per share in cash, with approximately 99.75% of shares voted in favor (35,119,793 for, 32,508 against, 55,248 abstain). The meeting also included a vote on executive compensation arrangements, with 30,620,395 shares in favor and 4,220,505 against.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
Item 5.07 discloses the results of a shareholder vote (via written consent) in which 68.71% of voting power approved granting the Board discretionary authority to effect a reverse stock split in a 1-for-2 to 1-for-6 range. This is a classic shareholder vote result disclosure, material because reverse stock splits can affect share price, liquidity, and listing eligibility, and would influence a reasonable investor's assessment of the company's capital structure and exchange listing prospects.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-22
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from DXC Technology's 2026 Annual Meeting held on July 21, 2026. The filing reports certified voting outcomes on five proposals: election of nine directors, ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, rejection of a term extension to the 2017 Omnibus Incentive Plan, and approval of a term extension to the 2017 Non-Employee Director Incentive Plan. The detailed vote tallies for each proposal are provided, making this a textbook shareholder_vote_results disclosure that is material to investors assessing governance and capital allocation decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-22
Item 5.07
ChargePoint held its 2026 Annual Meeting of Stockholders on July 21, 2026, with shareholders voting on three proposals: election of Class III directors (Bruce Chizen, Michael Linse, and Richard Wilmer), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. Final vote tallies certified by the Inspector of Election are disclosed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-22
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of WM Technology's 2026 Annual Meeting of Stockholders held on July 16, 2026. The filing presents voting outcomes for four proposals: (1) declassification of the board (failed), (2) advisory say-on-pay vote (passed), (3) auditor ratification (passed), and (4) election of three Class II directors (passed). The detailed vote tallies and quorum information (84% attendance) are material to shareholders assessing governance and board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-21
Item 5.07
Shareholders voted at a reconvened meeting on July 20, 2026, approving two proposals: warrant exercisability (93.3% in favor) and an increase in authorized share capital by 10 million shares (89.8% in favor). Both proposals passed by majority vote, materially affecting the company's capital structure and warrant obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-21
Item 5.07
This Item 5.07 discloses the results of Rein Therapeutics' 2026 Annual Meeting of Stockholders held on July 20, 2026, including voting outcomes on director elections (Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D.), approval of an amendment to increase authorized common shares from 100 million to 200 million, ratification of CBIZ CPAs P.C. as independent auditor, and advisory approval of named executive officer compensation. The filing presents detailed vote tallies for each matter, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-21
Item 5.07
Aware Inc held its Annual Meeting of Shareholders on July 15, 2026, with final voting results reported on four matters: election of Class III directors (Amlani and Faubert), advisory approval of named executive officer compensation, ratification of RSM US LLP as independent auditor, and approval of a 1,000,000-share increase to the 2023 Equity and Incentive Plan.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 92%
filed 2026-07-21
Item 7.01
The filing discloses results of a shareholder vote at an annual meeting held on July 21, 2026, where shareholders approved all proposals including an amendment to extend the SPAC's deadline to complete an initial business combination. This is a direct disclosure of shareholder vote results under Item 5.07, and the extension approval is material to investors as it affects the timeline and viability of the proposed business combination with a critical mineral target company announced on July 17, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-21
Item 5.07
Stockholders voted on July 21, 2026 to approve an assignment for the benefit of creditors followed by voluntary dissolution and liquidation, with 13,348,600 votes in favor, 100,879 against, and 44,093 abstentions (69% quorum of outstanding voting power).
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-21
The 6-K discloses the results of Ohmyhome Limited's Annual General Meeting held on July 21, 2026, where shareholders voted on eleven proposals. The filing presents voting tallies (For/Against/Abstain) for each proposal, including material capital structure changes (authorized share capital increase, capital reduction, share subdivision, share consolidation), director re-appointments, and auditor ratification. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the capital restructuring proposals are material to investors' assessment of the company's share structure and dilution risk.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 85%
filed 2026-07-21
The 6-K discloses a "Consolidated Synthetic Voting Map" for an Extraordinary General Meeting scheduled for July 22, 2026, presenting consolidated remote voting instructions received by shareholders on items 2 and 3 (election of Board of Directors and Chairman). While technically pre-vote disclosure rather than final results, this represents material shareholder voting information on board composition and leadership—a governance matter affecting reasonable investor assessment of the company's direction and control.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-21
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Picard Medical's Annual Meeting of Stockholders held on July 17, 2026. The filing presents voting results for six matters: election of four directors, advisory approval of named executive officer compensation, frequency of future advisory votes on compensation, approval of a reverse stock split amendment (1-for-15 to 1-for-50 ratio), designation of Class B common stock with 20 votes per share, and ratification of MaloneBailey LLP as independent auditor. All matters were approved. The reverse stock split authorization and Class B voting structure are material governance and capital structure changes affecting shareholder rights and equity value.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-21
Item 5.07
Radnostix Inc. held its Annual Meeting on July 16, 2026, with shareholders voting on three proposals: election of five directors, ratification of independent auditor Haynie & Company, and approval of the 2026 Incentive Plan. Detailed vote tallies were disclosed for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-21
Item 5.07
VolitionRx held its annual meeting of stockholders on July 17, 2026, with voting results on five proposals: election of seven directors, ratification of auditor (Sadler, Gibb & Associates, LLC), advisory vote on named executive officer compensation, amendment to reduce authorized shares from 325 million to 150 million, and approval of the 2026 Stock Incentive Plan.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-21
The 6-K discloses the results of an extraordinary general meeting held on July 21, 2026, where shareholders voted on a 1-for-10 share consolidation resolution. The resolution passed with 99.34% of votes cast in favor. Share consolidations are material capital structure changes that affect all shareholders' holdings and voting power, and the filing explicitly reports the voting results by share class and vote count, matching the `shareholder_vote_results` taxonomy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-21
The filing discloses results of My Size, Inc.'s 2026 annual stockholder meeting held on July 21, 2026, under Item 5.07. The company reports voting outcomes for five proposals: election of two Class II directors (both passed), an advisory say-on-pay vote (passed), authorization for reverse stock splits up to 1-for-30 (passed), approval of blank check preferred stock authorization (failed to achieve majority of outstanding shares), and ratification of Somekh Chaikin as independent auditor (passed). The failure of the blank check preferred stock proposal is material to investors assessing the company's capital structure flexibility.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-20
The 6-K discloses the results of Formula Systems' 2026 annual general meeting of shareholders held on July 20, 2026. The filing reports voting outcomes on eight proposals, including re-election of five board members (Marek Panek, Rafal Kozlowski, Itay Meroz, Karolina Rzonca-Bajorek, and Gabriela Żukowicz) and re-appointment of the independent auditor (Ziv Haft/BDO Israel), all of which were approved. This is a classic shareholder_vote_results disclosure under the 8-K taxonomy Item 5.07 equivalent.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-20
Item 5.07
ZeroStack Corp. held an annual shareholder meeting at which eight proposals were submitted to a vote, including director elections, auditor reappointment, equity issuance approval, equity plan amendments, executive compensation approval, incorporation jurisdiction change, bylaw amendment establishing a classified board with staggered director terms, and meeting adjournment authority. All eight proposals were approved by shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-20
Item 5.07
This Item 5.07 disclosure reports the results of Transcode Therapeutics' 2026 Annual Meeting of Stockholders held on July 20, 2026. The filing details voting outcomes on seven proposals, including approval of convertible preferred stock issuances (Proposals 1–2), a Standby Equity Purchase Agreement and convertible notes (Proposal 3), election of six directors (Proposal 4), amendment to the 2021 Stock Option and Incentive Plan (Proposal 5), ratification of the independent auditor (Proposal 6), and adjournment authority (Proposal 7). All proposals were approved. The disclosure is material because shareholder approval of dilutive equity issuances and director elections directly affects investor interests and capital structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-20
Item 5.07
Stockholders approved by written consent on July 19, 2026, the issuance of PIPE shares, convertible notes, warrants, and sponsor incentive shares under Nasdaq Rule 5635(b), and the adoption of a new equity plan under Nasdaq Rule 5635(c).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-20
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Healthcare Triangle's July 17, 2026 annual shareholder meeting. The filing presents voting tallies for nine proposals, including director elections, auditor ratification, stock plan amendments, and critically, approval of multiple dilutive issuances (2.8M shares to SecureKloud, up to 11.9M shares in the Teyame transaction, convertible debentures, and ELOC securities). These shareholder approvals of substantial equity issuances are material to investors assessing dilution and capital structure.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-20
This 6-K discloses the results of shareholder votes held on July 20, 2026, including three separate meetings (Class A, Class B, and Extraordinary General Meeting). The disclosure reports voting results on material matters including: (1) increase of voting rights for Class B shares from 30 to 800 votes; (2) repurchase of 3.77 million Class A shares held by the CEO's entity; (3) issuance of 3.77 million Class B shares to the CEO's entity; (4) increase in authorized share capital; (5) adoption of amended articles of association; and (6) approval of a VIE acquisition of Beijing Tongsheng Technology with issuance of 64.2 million Class A shares as consideration. These are material governance and capital structure changes requiring shareholder approval.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 15%
filed 2026-07-20
This is a major holdings notification (TR-1 form) disclosing that The Capital Group Companies, Inc. and Capital Research and Management Company crossed above the 17.00% voting threshold in Ryanair Holdings PLC on 16 July 2026, increasing from 16.08% to 17.03%. This is a material change in share ownership structure that would affect investor assessment of control and influence.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-17
Item 5.07
This Item 5.07 discloses the results of a special stockholder meeting held on July 16, 2026, where shareholders voted on three proposals, including approval of a merger agreement with KL Criss Cross Intermediate, LLC. Proposal 1 (the Merger Agreement Proposal) was approved with 23,356,105 votes in favor versus 12,309 against, and Proposal 2 (Advisory Merger-Related Compensation) was also approved. This is a classic shareholder vote results disclosure that is material because it confirms stockholder approval of a transformative merger that will result in the company being delisted from NASDAQ and deregistered under the Securities Exchange Act.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-17
The filing discloses results of the 2026 Annual Meeting of Stockholders held on July 14, 2026, including voting outcomes on three proposals: election of five board directors (Proposal 1), ratification of Weinberg & Company as independent auditor (Proposal 2), and adjournment authority (Proposal 3). This is a classic Item 5.07 shareholder vote results disclosure with detailed vote tallies for each nominee and proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-16
Item 5.07
Stockholders approved four substantive proposals at a Special Meeting: approval of warrant issuances from a registered direct offering and private placement, authorization to increase authorized common shares from 260 million to 600 million, and authorization for a reverse stock split at a 1-for-10 to 1-for-50 ratio. The certified voting results, including vote counts for, against, abstentions, and broker non-votes for each matter, are disclosed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-16
Item 5.07
Entera Bio held its 2026 Annual Meeting of Shareholders on July 14, 2026, with voting results disclosed covering ten proposals including director elections (Sean Ellis, Steven D. Rubin, Geno H. Germano), executive and director compensation approvals, equity plan amendments, and auditor ratification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-16
Item 5.07
IRIDEX Corporation held its 2026 Annual Meeting of Stockholders on July 10, 2026, with voting results confirming the election of five directors (Nick Chen, Beverly A. Huss, Patrick Mercer, William Moore, and Scott Shuda), ratification of BPM LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-16
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from BioAtla's Annual Meeting held July 16, 2026. The filing presents final voting tallies for three proposals: election of two Class III directors (Jay M. Short and Edward Williams), ratification of Ernst & Young LLP as independent auditor, and a non-binding advisory vote on named executive officer compensation. All three proposals passed with majority support, making this a routine but material governance disclosure that affects investor understanding of board composition and auditor appointment.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 75%
filed 2026-07-16
EX-99.1
Blue Gold Ltd is soliciting shareholder votes on two material proposals at an Extraordinary General Meeting scheduled for July 24, 2026: (1) authorization for a reverse stock split at a ratio between 1:2 and 1:200 to address Nasdaq minimum bid price compliance, and (2) amendment and restatement of the Memorandum and Articles of Association to reflect the reverse split. The reverse stock split is material to investors as it directly addresses the company's trading price and listing status in response to delisting risk.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-16
The 6-K discloses the results of an Extraordinary General Meeting held on July 13, 2026, where shareholders voted on three proposals: (1) revision of terms for allotment of up to 5,000,000 Class B shares to Xingji Zhangpingting Limited with board-determined consideration; (2) approval of an offering of up to 10,000,000 Class A shares and filing of a Form F-1 registration statement with the SEC; and (3) authorization to adjourn the meeting if necessary. All three proposals passed with overwhelming majorities (99.99% for Proposals 1 and 2, 100% for Proposal 3). The approval of a material equity offering and share allotment makes this material to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-16
Item 5.07 discloses the results of Versus Systems' annual shareholder meeting held July 16, 2026, with voting results for the election of four directors (Juan Carlos Barrera, David Catzel, Aric Spitulnik, and Luis Goldner) and a proposal to adjourn the meeting. All proposals were approved with clear majorities. This is a standard shareholder vote results disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-07-16
The 6-K discloses the results of an Extraordinary General Meeting held on July 10, 2026, where shareholders voted on seven proposals. The filing presents detailed vote tallies for each proposal, including the creation of Class A shares with 100 votes per share, a massive increase in authorized share capital (from 200 million to 100 trillion shares), and approval of amended memorandum and articles of association. These governance and capital structure changes are material to investors and directly correspond to Item 5.07 (shareholder vote results).
View raw filing on EDGAR →